MI-192
目录号 : GC11949A selective HDAC2/3 Inhibitor
Cas No.:1415340-63-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
MI-192 is a histone deacetylases (HDACs) inhibitor that preferentially inhibits HDAC2 and HDAC3 with IC50 values of 30 nM and 16 nM, respectively [1].
Histone acetylation is the most commonly employed mechanism utilized by transcription factors to activate gene expression. Conversely, histone deacetylation is the most common mechanism used to inactivate genes. Histone deacetylase inhibitors (HDACIs) are in advanced clinical development as cancer therapeutic agents [1].
MI-192 is a novel benzamide-based compound that had marked selectivity for the class I enzymes, HDAC2 and HDAC3. In HeLa cell extracts, MI-192 inhibited HDAC activity with IC50 value of 1.5 μM. MI-192 selectively inhibited recombinant HDAC2 and HDAC3 with IC50 values of 30 nM and 16 nM, respectively over HDAC1, 4, 6, 7, and 8 (IC50s = 4.8, 5, >10, 4.1, and >10 μM, respectively). MI-192 showed the greatest growth inhibitory effect against the leukemic cell lines with an effective dose of 0.1-0.4 μM. MI-192 was cytotoxic and promoted apoptosis and differentiation in leukaemic cell lines [1]. In the human prostate cancer cell line PC3, MI-192 significantly increased tubulin acetylation and ablated the dynamic behaviour of microtubules in live cells [2].
References:
[1]. Boissinot, M.,Inman, M.,Hempshall, A., et al. Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192. Leukemia Research 36, 1304-1310 (2012).
[2]. Bacon T, Seiler C, Wolny M, et al. Histone deacetylase 3 indirectly modulates tubulin acetylation. Biochem J. 2015 Dec 15;472(3):367-77.
Cas No. | 1415340-63-4 | SDF | |
化学名 | N-(2-aminophenyl)-4-[(3,4-dihydro-4-methylene-1-oxo-2(1H)-isoquinolinyl)methyl]-benzamide | ||
Canonical SMILES | O=C1N(CC2=CC=C(C(NC3=CC=CC=C3N)=O)C=C2)CC(C4=CC=CC=C41)=C | ||
分子式 | C24H21N3O2 | 分子量 | 383.4 |
溶解度 | ≤5mg/ml in DMSO;1mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.6082 mL | 13.0412 mL | 26.0824 mL |
5 mM | 0.5216 mL | 2.6082 mL | 5.2165 mL |
10 mM | 0.2608 mL | 1.3041 mL | 2.6082 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。